EGFR and non-small cell lung carcinoma: IGF-1R is also predictive of response to treatment, as demonstrated by the apparent up-regulation in IGF-1R in patients with NSCLC who have developed a resistance to gefitinib, an epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) [87].